JCA at Sixteen Months, Survodutide Phase III, and ISPOR 2026

Five developments shaping HEOR and market access this week.The EU Joint Clinical Assessment at sixteen months — structural tensions unresolved, thirteen PICOs in a single assessment, and why the first published reports are the real test of whether national HTA bodies actually use the output.Boehringer's survodutide Phase III posted 16.6% mean weight loss versus placebo. The clinical signal is strong. The HTA road is not — European payers reimburse cardiovascular outcomes, not weight loss numbers, and the comparator is semaglutide.ISPOR 2026 opens in Philadelphia this week. AI moves to number one on the trends report. Value-based healthcare enters the top three for the first time.Big pharma quietly restructuring internal HEOR functions. The independence of the evidence function is what gives it credibility in front of an HTA committee.Norway's New Methods framework updated its process for medical technologies, effective 1 May 2026.Hosted by Marcus and Sara. outcomes-analytica.no